-
Rams ace Nacua apologizes over 'antisemitic' gesture furor
-
McIlroy wins BBC sports personality award for 2025 heroics
-
Napoli beat Milan in Italian Super Cup semi-final
-
Violence erupts in Bangladesh after wounded youth leader dies
-
EU-Mercosur deal delayed as farmers stage Brussels show of force
-
US hosting new Gaza talks to push next phase of deal
-
Chicago Bears mulling Indiana home over public funding standoff
-
Trump renames Kennedy arts center after himself
-
Trump rebrands housing supplement as $1,776 bonuses for US troops
-
Harrison Ford to get lifetime acting award
-
Trump health chief seeks to bar trans youth from gender-affirming care
-
Argentine unions in the street over Milei labor reforms
-
Trump signs order reclassifying marijuana as less dangerous
-
Famed Kennedy arts center to be renamed 'Trump-Kennedy Center'
-
US accuses S.Africa of harassing US officials working with Afrikaners
-
Brazil open to EU-Mercosur deal delay as farmers protest in Brussels
-
Wounded Bangladesh youth leader dies in Singapore hospital
-
New photo dump fuels Capitol Hill push on Epstein files release
-
Brazil, Mexico seek to defuse US-Venezuela crisis
-
Assange files complaint against Nobel Foundation over Machado win
-
Private donors pledge $1 bn for CERN particle accelerator
-
Russian court orders Austrian bank Raiffeisen to pay compensation
-
US, Qatar, Turkey, Egypt to hold Gaza talks in Miami
-
Lula open to mediate between US, Venezuela to 'avoid armed conflict'
-
Brussels farmer protest turns ugly as EU-Mercosur deal teeters
-
US imposes sanctions on two more ICC judges for Israel probe
-
US accuses S. Africa of harassing US officials working with Afrikaners
-
ECB holds rates as Lagarde stresses heightened uncertainty
-
Trump Media announces merger with fusion power company
-
Stocks rise as US inflation cools, tech stocks bounce
-
Zelensky presses EU to tap Russian assets at crunch summit
-
Pope replaces New York's Cardinal Dolan with pro-migrant bishop
-
Odermatt takes foggy downhill for 50th World Cup win
-
France exonerates women convicted over abortions before legalisation
-
UK teachers to tackle misogyny in classroom
-
Historic Afghan cinema torn down for a mall
-
US consumer inflation cools unexpectedly in November
-
Danish 'ghetto' residents upbeat after EU court ruling
-
ECB holds rates but debate swirls over future
-
Pope replaces New York's Cardinal Timothy Dolan with little-known bishop
-
Bank of England cuts interest rate after UK inflation slides
-
Have Iran's authorities given up on the mandatory hijab?
-
Spain to buy 100 military helicopters from Airbus
-
US strike on alleged drug boat in Pacific kills four
-
Thailand strikes building in Cambodia's border casino hub
-
Protests in Bangladesh as India cites security concerns
-
European stocks rise before central bank decisions on rates
-
Tractors clog Brussels in anger at EU-Mercosur trade deal
-
Not enough evidence against Swedish PM murder suspect: prosecutor
-
Nepal's ousted PM Oli re-elected as party leader
Man who let snakes bite him 200 times spurs new antivenom hope
Tim Friede was feeling particularly down on the day after the September 11 attacks, so he went to his basement and let two of the world's deadliest snakes bite him.
Four days later, he woke up from a coma.
"I know what it feels like to die from snakebite," Friede told AFP via video call from his home in the small US town of Two Rivers, Wisconsin.
This experience might put most people off snakes entirely, but Friede simply vowed to be more careful next time.
From 2000 to 2018, he allowed himself to be bitten by snakes more than 200 times. He also injected himself with their venom over 650 times.
Friede endured this pain because he wanted to achieve total immunity to venom, a practice called mithridatism which should not be tried at home.
After a couple of years, Friede started to believe he could be the basis for a better kind of antivenom. The former truck mechanic, who does not have a university degree, long struggled to be taken seriously by scientists.
But last month, a study published in the prestigious Cell journal showed that antibodies from his blood protect against a range of snake venom.
The researchers now hope Friede's hyper-immunity could even lead to the development of a universal antivenom.
This would fill a major need, because currently most antivenoms only cover one or a few of the world's 600 venomous snakes.
Up to 138,000 people are killed by snakebites a year, while 400,000 suffer amputations or other disabilities, according to the World Health Organization.
These figures are believed to be vastly underestimated because snakebite victims typically live in poorer, remote areas.
- 'Pain every time' -
Friede's first bite was from a harmless garter snake when he was five years old.
"I was afraid, I cried, I ran away," said Friede, now 57.
Then he started bringing snakes home and hiding them in pickle jars. His mother sought counselling, but his interest in snakes persisted.
Things escalated after Friede attended a class that taught him how to "milk" snakes for their venom.
How antivenom is made has changed little over the last 125 years.
Small doses of snake venom are injected into animals such as horses, which produce antibodies that can be extracted and used as antivenom.
However this antivenom usually only works for bites from that particular species of snake -- and it includes other antibodies from horse that can cause serious side-effects including anaphylactic shock.
"I thought, well, if they make antivenom in horses, why can't I just use myself as a primate?" Friede said.
He started working through the venom from all the deadly species he could get his hands on, such as cobras, taipans, black mambas and rattlesnakes.
"There is pain every time," he said.
- 'Proud' -
For years, the scientists he contacted to take advantage of his immunity refused to bite.
Then in 2017, immunologist Jacob Glanville, who previously worked on universal vaccines, turned his attention towards antivenom.
Glanville told AFP he had been looking for "a clumsy snake researcher who'd been bit accidentally a couple times," when he came across a video of Friede taking brutal back-to-back snake bites.
When they first spoke, Glanville said he told Friede: "I know this is awkward, but I would love to get my hands on some of your blood."
"I've been waiting for this call for a long time," came the response, Glanville said.
The antivenom described in the Cell paper includes two antibodies from Friede's blood, as well as a drug called varespladib.
It offered mice full protection against 13 of the 19 snake species tested, and partial protection for the remaining six.
The researchers hope a future cocktail will cover far more snakes -- particularly vipers -- with further trials planned on dogs in Australia.
Timothy Jackson of the Australian Venom Research Unit praised the immunological research, but questioned whether a human needed to be involved, pointing to synthetically developed antibodies.
Glanville said the ultimate goal of his US-based firm Centivax was to develop a universal antivenom administered by something like an EpiPen, potentially produced in India to keep the costs down.
Friede said he was "proud" to have made a "small difference" in medical history.
Now working for Centivax, Friede stopped self-inflicting himself with venom in 2018 to save the firm from liability issues.
But he hopes to get bitten by snakes again in the future.
"I do miss it," he said.
C.Kovalenko--BTB